<DOC>
	<DOCNO>NCT01683188</DOCNO>
	<brief_summary>This research study evaluate treatment metastatic melanoma patient combination drug . The combination study vemurafenib ( also know Zelboraf® ) High Dose Interleukin-2 ( abbreviate HD IL-2 known Proleukin® ) . The combination vemurafenib HD IL-2 immunotherapy may enhance response .</brief_summary>
	<brief_title>HD IL-2 + Vemurafenib Patients With BRAF Mutation Positive Metastatic Melanoma</brief_title>
	<detailed_description>This open-label , uncontrolled two-arm , multi-center study patient metastatic melanoma BRAFV600 oncogene mutation . Patients initially receive treatment vemurafenib intersperse two course High Dose IL-2 ( HD IL-2 ) . Patients eligible study melanoma positive BRAFV600 mutation , vemurafenib therapy 0-18 week , respond stable disease vemurafenib , meet requirement dose HD IL-2 protocol inclusion exclusion criterion . Two Cohorts enrol , differ characterize prior HD IL-2 treatment : Cohort 1 : consist 135 patient naïve vemurafenib HD IL-2 therapy . Patients Cohort 1 initial evaluation receive define 6 ( ± 1 ) week course vemurafenib begin HD IL-2 . This Cohort use define study size statistical validity comparator historic control ( use data BRAF positive patient Melanoma SELECT study Protocol IIT10PLK06 ) . Cohort 2 : consist 50 patient vemurafenib therapy &gt; 7 18 week stable respond disease start HD IL-2 . Patients Cohort 2 initial evaluation begin HD IL-2 treatment &gt; 7 18 week treatment vemurafenib . This Cohort design evaluate whether additive synergistic clinical benefit toxicity observe BRAFV600 mutation positive metastatic melanoma patient treat vemurafenib single agent &gt; 7 to18 week prior first course HD IL-2 therapy conjunction continue vemurafenib . Patients cohort discontinue dose vemurafenib prior treatment HD IL-2 resume dose discharge . Patients receive two course ( four cycle ) HD IL-2 evaluate disease response 10 week ( ±3 week ) start HD IL-2 dosing , 26 week ( ±3 week ) start HD IL-2 dosing . QTc interval review daily change cycle HD IL-2 dosing . Administration vemurafenib HD IL-2 accord respective Package Inserts accord Institution 's standard care . The investigator determine number HD IL-2 cycle patient receive , accord investigator 's discretion medical judgment .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Male female patient 18 year age old . Confirmed measurable metastatic melanoma BRAFV600 mutation . Patients least one metastatic melanoma lesion accessible . biopsy prior vemurafenib treatment archive tissue available . Meet requirement HD IL2 therapy per institutional guideline . Meet requirement vemurafenib therapy per institutional guideline . Patient must willing provide write Informed Consent participate study procedure describe 12PLK01 . Patients consent 12PLK01 also ask participate 10PLK13 PROCLAIM ( Proleukin® ) registry study . A patient consider eligible study participation follow exclusion criterion meet : Prior therapy metastatic disease follow : IL2 , Ipilimumab , highly selective BRAF , MEK , NRAS , cMET inhibitor ( e.g . GSK2118436 GSK1120212 ) TKIs . Exception : 6 week washout follow allow : Adjuvant Ipilimumab , Anti PD1 , Anti PD L1 Exclusion Cohort 1 : vemurafenib treatment &gt; 7 week . Exclusion Cohort 2 : vemurafenib treatment &lt; 7 week . ( eligible Cohort 1 ) &gt; 18 week . QTc interval &gt; 500ms . Patients know suspected infection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) infectious hepatitis . Pregnant , nurse plan become pregnant . Untreated brain metastasis . ( Brain metastasis treat , long require corticosteroid therapy without progression MRI assessment least 6 week definitive therapy acceptable . ) Received investigational drug within 30 day prior study dose . Patients may participate noninterventional observational clinical study ( y ) Concomitant disease condition would interfere conduct study would , opinion Investigator , pose unacceptable risk patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>skin cancer</keyword>
	<keyword>Stage IV</keyword>
</DOC>